Exicure appoints Josephine Cardarelli as president, CSO

Following its acquisition of GPCR Therapeutics USA earlier this year, Exicure (XCUR) has been advancing the Phase 2 trial with dedicated internal drug development experts. These scientific leaders bring broad experience spanning from basic research to regulatory approval and have decades of proven track records in developing innovative medicines. Josephine Cardarelli, Ph.D. joined as President and Chief Scientific Officer. She most recently served as Vice President of Cell Biology & Pharmacology at Bristol-Myers Squib (BMY). Nina Caculitan, Ph.D. has been appointed Head of Clinical, overseeing activities spanning manufacturing, regulatory affairs, clinical development, clinical operations and data analysis. Previously, she was a key contributor to understanding cellular mechanisms of antibody drug conjugate processing at Genentech (RHHBY). Devki Sukhtankar, Ph.D. has joined as Head of Preclinical Research and Translational Medicine, guiding cross-functional translational research efforts with a focus on integrating clinical data and advancing the pipeline into new indications. She brings over 15 years of experience in oncology, neurology and inflammatory diseases, where she has led preclinical programs with a focus on pharmacology and contributed to 20 peer-reviewed publications